Article Versions Notes

Afolabi BL, Mazhindu T, Zedias C, Borok M, Ndlovu N, Masimirembwa C, on behalf of Consortium for Genomics and Therapeutics in Africa (CGTA). Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe. Journal of Personalized Medicine. 2023; 13(4):588. https://doi.org/10.3390/jpm13040588

Afolabi, Boluwatife Lawrence, Tinashe Mazhindu, Chikwambi Zedias, Margaret Borok, Ntokozo Ndlovu, Collen Masimirembwa, and on behalf of Consortium for Genomics and Therapeutics in Africa (CGTA). 2023. "Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe" Journal of Personalized Medicine 13, no. 4: 588. https://doi.org/10.3390/jpm13040588

Afolabi, B. L., Mazhindu, T., Zedias, C., Borok, M., Ndlovu, N., Masimirembwa, C., & on behalf of Consortium for Genomics and Therapeutics in Africa (CGTA). (2023). Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe. Journal of Personalized Medicine, 13(4), 588. https://doi.org/10.3390/jpm13040588